Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (270) Arrow Down
Filter Results: (270) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (342)
    • News  (34)
    • Research  (270)
  • Faculty Publications  (228)

Show Results For

  • All HBS Web  (342)
    • News  (34)
    • Research  (270)
  • Faculty Publications  (228)
← Page 10 of 270 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • January 2023
  • Teaching Note

The Opioid Settlement and Executive Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
Citation
Purchase
Related
Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Executive Pay at AmerisourceBergen." Harvard Business School Teaching Note 123-067, January 2023.
  • March 2018 (Revised January 2019)
  • Case

Gilead Mexico

By: Michael Chu and V. Kasturi Rangan
With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of... View Details
Keywords: Health Care and Treatment; Price; Strategy; Management; Pharmaceutical Industry; Mexico
Citation
Educators
Purchase
Related
Chu, Michael, and V. Kasturi Rangan. "Gilead Mexico." Harvard Business School Case 318-111, March 2018. (Revised January 2019.)
  • 26 Apr 2023
  • Cold Call Podcast

How Martine Rothblatt Started a Company to Save Her Daughter

Keywords: Re: Debora L. Spar; Pharmaceutical; Pharmaceutical; Pharmaceutical
  • January 2017
  • Supplement

Medtronic: Making the Big Leap Forward (B)

By: William W. George and Monica Baraldi
On December 1, 2014, Medtronic announced that it had completed a $17 billion bond sale to finance the Covidien acquisition, officially completed on January 26, 2015. Medtronic’s legal headquarters moved to Ireland, while its operational headquarters remained in... View Details
Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States
Citation
Purchase
Related
George, William W., and Monica Baraldi. "Medtronic: Making the Big Leap Forward (B)." Harvard Business School Supplement 317-074, January 2017.
  • August 2022
  • Article

Availability of New Medicines in the U.S. and Germany From 2004 to 2018

By: Katharina Blankart, Huseyin Naci and Amitabh Chandra
Importance: Germany's unique approach to coverage determination and pricing has ensured that effective medicines remain on the market, often at prices reduced through negotiation. However, less is known about trade-offs of this approach with regard to initial... View Details
Keywords: Market Entry and Exit; Price; Market Timing; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States; Germany
Citation
Register to Read
Related
Blankart, Katharina, Huseyin Naci, and Amitabh Chandra. "Availability of New Medicines in the U.S. and Germany From 2004 to 2018." e2229231. JAMA Network Open 5, no. 8 (August 2022).
  • August 2024
  • Article

How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?

By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by... View Details
Keywords: Prescription Drugs; Coupons; Impact; Health Care and Treatment; Markets; Price; Spending; Pharmaceutical Industry; United States
Citation
Find at Harvard
Register to Read
Related
Dafny, Leemore S., Kate Ho, and Edward Kong. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?" American Economic Journal: Economic Policy 16, no. 3 (August 2024): 314–346.
  • September 2010
  • Teaching Note

Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)

By: Willy C. Shih
Teaching Note for 611009. View Details
Keywords: Value; Patents; Corporate Strategy; Competition; Research and Development; Lawsuits and Litigation; Pharmaceutical Industry; United States
Citation
Purchase
Related
Shih, Willy C. "Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)." Harvard Business School Teaching Note 611-010, September 2010.
  • December 2008 (Revised October 2013)
  • Case

Amylin Pharmaceuticals: Diabetes and Beyond (A)

By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)
  • October 2000
  • Case

Procter & Gamble Italy: The Pringles Launch (A)

By: Roy D. Shapiro
Procter & Gamble's (P&G) Pringles potato chips have been a very successful brand. This case reviews the development and first launch in the United States, then in markets around the world. Italy is one of the last countries where Pringles will be launched. Should P&G... View Details
Keywords: Globalized Markets and Industries; Brands and Branding; Marketing Strategy; Product Launch; Emerging Markets; Product Development; Adoption; Value Creation; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Shapiro, Roy D. "Procter & Gamble Italy: The Pringles Launch (A)." Harvard Business School Case 601-070, October 2000.
  • October 1992 (Revised September 1993)
  • Case

Nopane Advertising Strategy

By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
  • February 1998 (Revised October 1998)
  • Background Note

Note on New Drug Development in the United States

By: Stefan H. Thomke and Ashok Nimgade
An overview of the new drug development process in the United States, using the migraine drug Imitrex as an illustrative example. View Details
Keywords: Product Development; Research and Development; Health; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Note on New Drug Development in the United States." Harvard Business School Background Note 698-028, February 1998. (Revised October 1998.)
  • 01 Sep 2020
  • Cold Call Podcast

How to Launch a New Biosciences Product: Start Small or Dive in?

Keywords: Re: Jeffrey J. Bussgang; Pharmaceutical; Pharmaceutical
  • 10 Aug 2020
  • Research & Ideas

COVID's Surprising Toll on Careers of Women Scientists

COVID-19 is claiming an unexpected career toll among scientific researchers, and particularly on women, new research shows. If you are female, have young children, or work in a lab, you are more likely to feel the career-crunching effects dealt by the pandemic,... View Details
Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical; Pharmaceutical
  • September 2008
  • Case

Pfizer Inc: Building an Innovation Center

By: Stefan H. Thomke and Ashok Nimgade
The case describes Pfizer's efforts to build and run an innovation center in Cambridge, Massachusetts. As the center goes through different periods of leadership and strategic models, its relationship with the corporation and other research sites is explored. The case... View Details
Keywords: Innovation and Management; Innovation Strategy; Leadership; Organizational Culture; Research and Development; Pharmaceutical Industry; Cambridge
Citation
Educators
Purchase
Related
Thomke, Stefan H., and Ashok Nimgade. "Pfizer Inc: Building an Innovation Center." Harvard Business School Case 609-037, September 2008.
  • 18 Jul 2018
  • Research & Ideas

No More General Tso's? A Threat to 'Knowledge Recombination'

pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
Keywords: by Michael Blanding; Health; Food & Beverage; Accounting
  • March 2001 (Revised June 2017)
  • Teaching Note

Vyaderm Pharmaceuticals: The EVA Decision

By: Robert Simons and Indra A. Reinbergs
Teaching Note for (9-101-019). View Details
Keywords: Pharmaceutical Industry; Washington (state, US)
Citation
Purchase
Related
Simons, Robert, and Indra A. Reinbergs. "Vyaderm Pharmaceuticals: The EVA Decision." Harvard Business School Teaching Note 101-043, March 2001. (Revised June 2017.)
  • February 1992 (Revised April 1995)
  • Case

Pfizer: Global Protection of Intellectual Property

By: Lynn S. Paine and Michael Santoro
Top officials at Pfizer are assessing their strategy for improving protection of Pfizer's patents around the world. The outcome of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable intellectual property protection... View Details
Keywords: Patents; Trade; Policy; Government and Politics; Business Strategy; Agreements and Arrangements; Alliances; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; United States; Japan; Europe
Citation
Educators
Purchase
Related
Paine, Lynn S., and Michael Santoro. "Pfizer: Global Protection of Intellectual Property." Harvard Business School Case 392-073, February 1992. (Revised April 1995.)
  • 21 Nov 2006
  • First Look

First Look: November 21, 2006

exhibits. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=607019 Wendy Kopp and Teach for America (A) Harvard Business School Case 406-125 In 1995, Wendy Kopp, founder and president of Teach for America,... View Details
Keywords: Sean Silverthorne
  • 28 Aug 2017
  • Research & Ideas

Should Industry Competitors Cooperate More to Solve World Problems?

to be innovative, really providing service to customers and attracting top talent. They are now becoming utilities, facing an incredible amount of regulation largely because of their own conduct failures. Third, they could reduce risk from exposure to major scandals.... View Details
Keywords: by Sean Silverthorne; Financial Services; Manufacturing; Agriculture & Agribusiness; Mining
  • February 2024
  • Teaching Note

Compass Pathways: Pioneering Psychedelic Treatment

By: Tiona Zuzul
Teaching Note for HBS Case No. 724-412. View Details
Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Care and Treatment; Pharmaceutical Industry; Europe; United States; United Kingdom
Citation
Purchase
Related
Zuzul, Tiona. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Teaching Note 724-457, February 2024.
  • ←
  • 10
  • 11
  • 12
  • 13
  • 14
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.